Traditional Chinese Medicine (TCM), including herbal remedies and animal secretions like HuaChansu, also called Cinobufacini, has gained attention for its therapeutic efficacy in cancer treatment. HuaChansu, extracted from the skin of toads from the genus Bufo, has been used traditionally for various diseases and recently explored for its anti-cancer properties attributed to bufadienolides like bufalin, resibufogenin, and cinobufagin. Clinical studies and meta-analyses have evaluated its efficacy and safety across various cancers. For hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer, pilot studies and clinical trials showed HuaChansu's potential for disease stabilization with minimal toxicity. In breast cancer, a meta-analysis suggested that HuaChansu combined with chemotherapy improves response rates and quality of life. Studies on gallbladder and gastric cancers indicated similar benefits, enhancing therapeutic effects and reducing side effects. In lung cancer, HuaChansu improved survival rates and quality of life when combined with chemotherapy, though placebo-controlled trials are needed. For liver cancer, meta-analyses and randomized controlled trials demonstrated improved survival rates and reduced recurrence when HuaChansu was used with transarterial chemoembolization. These findings underscore HuaChansu potential as a complementary cancer treatment, warranting further research to optimize its dosage and administration for enhanced efficacy.